Phospho-beta Amyloid (Thr743) Polyclonal Antibody

A4 amyloid protein, A4, AAA, ABETA, ABPP, AD1, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), Alzheimer disease amyloid protein, Amyloid beta (A4) precursor protein, Amyloid beta A4 protein, Amyloid beta protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, Amyloid precursor protein, APP, APPI, Beta amyloid peptide, Beta-amyloid precursor protein, Beta-APP40, Beta-APP42, C31, Cerebral vascular amyloid peptide, CTFgamma, CVAP, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), peptidase nexin II, PN 2, PN II, PN-II, PN2, PreA4, Protease nexin II, Protease nexin-II, S-APP-alpha, S-APP-beta

Abeta derives from APP via proteolytic cleavage by proteases called alpha-, beta- and gamma-secretase. The alpha-secretase cleavage precludes the formation of Abeta, while the beta- and gamma-cleavages generate APP components with amyloidogenic features. Amyloid beta A4 precursor protein(APP), encoded by APP gene which locate on human chromosome 21q, is a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. APP expressed in all fetal tissues and is pronounced in brain, kidney, heart and spleen, but weak in liver. Defects in APP are the cause of Alzheimer disease type 1 (AD1). This antibody can recogniaze the N-terminus of human APP: Soluble APP-alpha and Soluble APP-beta.

Store at -20C. Avoid freeze / thaw cycles.

PBS with 0.02% sodium azide, 0.5% BSA and 50% glycerol, pH7.4

WB 1:500-1:2000, IHC 1:100-1:300, IF 1:200-1:1000, ELISA 1:10000

87kDa